Original paper
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA ‐A24‐positive pancreatic adenocarcinoma
Abstract
The prognosis of advanced pancreatic adenocarcinoma is still extremely poor. This study sought to determine the efficacy of, and immunological response to, peptide vaccination therapy in patients with this disease. In this multicenter randomized phase II study, patients with advanced pancreatic adenocarcinoma after gemcitabine and/or tegafur/gimeracil/oteracil were randomly assigned to 3 groups that each received a 2-step treatment course. In...
Paper Details
Title
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA ‐A24‐positive pancreatic adenocarcinoma
Published Date
Jul 23, 2019
Journal
Volume
110
Issue
8
Pages
2378 - 2385
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History